Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.
EIDOSEveryone Is Doing Outrageous Sex (organization/website
EIDOSEleven Idiots Dreaming of Success
References in periodicals archive ?
Goldman Sachs concurred, saying it believed Eidos will achieve the bank's full year estimates, and putting a 53.2 pounds 12-month share price target on the firm.
The United Kingdom-based computer games publisher Eidos Plc announced on Thursday (4 March) that it had agreed to acquire the Danish computer games developer IO Interactive for an undisclosed sum.
They included the fact that a combination of Eidos and SCi will not result in a significantly larger business within an industry that it said required scale to compete effectively.
Electronic Arts Inc (EA) (Nasdaq:ERTS), an interactive, entertainment, software company, announced on Monday (15 September) that the company has signed an agreement with Eidos Interactive (LSE: SEG), a creator of videogame properties, that sees the exclusive multi-regional distribution and licensing rights to selected titles from the Eidos catalogue being granted to EA Mobile for mobile devices.
London, January 10 (ANI): Considering digital heroine Lara Croft's waning popularity in the United States, video games publisher Eidos has decided to give the fictional character a makeover.
Tim Ryan, chairman of Eidos, said the offer provided shareholders with an attractive price and certainty amid a challenging market backdrop.
GAMES publisher Eidos lifted sales by more than a quarter - thanks mainly to the launch of a new title in the Lara Croft series.
But Eidos warned that the cost of developing games was rising, increasing the risk involved, and said "scale" was needed to create and sell top-quality games.
EIDOS Interactive is set to revolutionise its Championship Manager franchise by offering a downloadable PC version of the new game to fans on a 'pay what you want' model allowing you to own the game from as little as a penny.
Release date- 18062019 - SAN FRANCISCO - Eidos Therapeutics, Inc.
Roth Capital analyst Yasmeen Rahimi believes that Eidos Therapeutics' ATTRibute-CM "smart trial design offers the best of both worlds" with two approvable endpoints, namely a 12-month, placebocontrolled study with primary endpoint of change from baseline in six-minute walk distance, and reduction in all-cause mortality and frequency of CV-related hospitalizations over 30 months.
Biopharmaceutical company Eidos Therapeutics Inc (Nasdaq:EIDX) said on Tuesday that it has priced its initial public offering of 6,250,000 common stock.